|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 在经历 transcatheter 的病人的 atrial 纤维性颤动的临床、预示的含意大动脉的阀门培植显示文摘 AIM: To study a cohort of consecutive patients under-going transcatheter aortic valve implantation (TAVI) and compare the outcomes of atrial fibrillation (AF) patients vs patients in sinus rhythm (SR). METHODS: All consecutive patients undergoing TAVI in our hospital were included. The AF group comprised patients in AF at the time of TAVI or with history of AF, and were compared with the SR group. Procedural, echocardiographic and follow-up variables were compared. Likewise, the CHA 2 DS 2-VASC stroke risk score and HAS-BLED bleeding risk score and antithrombotic treatment at discharge in AF patients were compared with that in SR patients. RESULTS: From a total of 34 patients undergoing TAVI, 17 (50%) were allocated to the AF group, of whom 15 (88%) were under chronic oral anticoagulation. Patients in the AF group were similar to those in the SR group except for a trend (P = 0.07) for a higher logistic EuroSCORE (28% vs 19%), and a higher prevalence of hypertension (82% vs 53%) and chronic renal failure (17% vs 0%). Risk of both stroke and bleeding was high in the AF group (mean CHA 2 DS 2-VASC 4.3, mean HAS-BLED 2.9). In the AF group, treatment at discharge included chronic oral anticoagulation in all except one case, and in association with an antiplatelet drug in 57% of patients. During a mean follow-up of 11 mo (maximum 32), there were only two strokes, none of them during the peri-procedural period: one in the AF group at 30 mo and one in the SR group at 3 mo. There were no statistical differences in procedural success, and clinical outcome (survival at 1 year 81% vs 74% in AF and SR groups, respectively, P = NS). CONCLUSION: Patients in AF undergoing TAVI show a trend to a higher surgical risk. However, in our cohort, patients in AF did not have a higher stroke rate compared to the SR group, and the prognosis was similar in both groups. | Pablo Salinas Raúl Moreno Luis Calvo Santiago Jiménez-Valero Guillermo Galeote Angel Sánchez-Recalde Teresa López-Fernández Sergio Garcia-Blas Diego Iglesias Luis Riera Isidro Moreno-Gómez Jose María Mesa Ignacio Plaza Rocio Ayala Rosa Gonzalez José-Luis López-Sendón | 2012 | World Journal of Cardiology2012，4，1： | 2 |
| 2 | 显示文摘 | Hanson CA Rajkumar SV | 2000 | Blood2000，96，： | 1 |
| 3 | Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia:an Olmsted County Study,1976-1995显示文摘 | Mesa RA Silverstein MN Jacobsen SJ | 1999 | Am J Hematol1999，61，1： | 1 |
| 4 | 显示文摘 | Hanson CA Yoon SY | 2000 | Blood2000，96，： | 1 |
| 5 | Lenalidomide and prednisone for myelofibrosis : Eastern Cooperative Oncology Group ( ECOG ) phase 2 trial E4903 显示文摘 | Mesa RA Yao X Cripe LD | 2010 | Blood2010，116，22： | 1 |
| 6 | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis显示文摘 | VERSTOVSEK S KANTARJIAN H MESA RA | 2010 | NEnglJMed2010，363，12： | 1 |
| 7 | Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not显示文摘 | Tefferi A Mesa RA Pardanani A | 2009 | Am J Hematol2009，84，5： | 1 |
| 8 | A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis 显示文摘 | VERSTOVSEK S MESA RA GOTLIB J | 2012 | NEnglJMed2012，366，9： | 1 |
| 9 | Adverse events after,imatinib mesylate therapy显示文摘 | Elliortt MA Mesa RA Tefferi A | 2002 | N Engl J Med2002，346，9： | 1 |
| 10 | Ruxolitinib, a selective Jakl and Jak2 inhibitor for the treatment of myeloproliferative neoplasms and psomasis显示文摘 | Mesa RA | 2010 | Drug2010，13，6： | 1 |
| 11 | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibosis 显示文摘 | Verstovsek S Kantar JH Mesa RA | 2010 | N Engl J Med2010，363，12： | 1 |
| 12 | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis显示文摘 | Verstovsek S Kantarjian H Mesa RA | 2010 | N Engl J Med2010，363，： | 1 |
| 13 | International Working Group (IWG) consensus criteria for treat ment response in myelofibrosis with myeloid metaplasia:on behalf of the IWG for myelofibrosis research and treatment (IWG-MRT)显示文摘 | Tefferi A Barosi G Mesa RA | 2006 | {H}Blood2006，，5： | 1 |
| 14 | Therapy for myeloproliferative neoplasms: when, which agent, and how 显示文摘 | Geyer I-IL Mesa RA | | Blood0，124，5： | 1 |
| 15 | Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symp- tomatic improvement显示文摘 | Mesa RA Kantarjian H Tefferi A | 2011 | Cancer2011，117，： | 1 |
| 16 | A double -blind, placebo - controlled trim of ruxolitinib for myelofibrosis 显示文摘 | Verstovsek S Mesa RA Goflib J | 2012 | New Engl J Med2012，366，： | 1 |
| 17 | Therapy for MPNs:when,which agent,and how? 显示文摘 | Geyer HL Mesa RA | 2014 | Hematology Am Soc Hematol Educ Program2014，2014，1： | 1 |
| 18 | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis 显示文摘 | Verstovsek S Mesa RA Gotlib J | 2012 | N Engl J Med2012，366，9： | 1 |
| 19 | JAK2 (V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia 显示文摘 | Mesa RA PowellH LashoT etal | 2006 | Leuk Res2006，30，11： | 1 |
| 20 | Tip ifarnib: famesyl transferase inhibition at a cross2roads 显示文摘 | Mesa RA | 2006 | Expert Rev Anticancer Ther2006，6，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员